JP2024534420A - 環状スルホンアミドリボヌクレオチドレダクターゼ(rnr)阻害剤およびその使用 - Google Patents

環状スルホンアミドリボヌクレオチドレダクターゼ(rnr)阻害剤およびその使用 Download PDF

Info

Publication number
JP2024534420A
JP2024534420A JP2024516798A JP2024516798A JP2024534420A JP 2024534420 A JP2024534420 A JP 2024534420A JP 2024516798 A JP2024516798 A JP 2024516798A JP 2024516798 A JP2024516798 A JP 2024516798A JP 2024534420 A JP2024534420 A JP 2024534420A
Authority
JP
Japan
Prior art keywords
alkyl
pharma
stereoisomer
tautomer
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024516798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534420A5 (cg-RX-API-DMAC7.html
Inventor
ビー. ピンカートン,アンソニー
モーガー,ジャック
ファム ホン チュオン,イエン
ジャネット エルスドン,レイチェル
トッド マイヤー,ステファン
Original Assignee
バウンドレス バイオ,インク.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バウンドレス バイオ,インク. filed Critical バウンドレス バイオ,インク.
Publication of JP2024534420A publication Critical patent/JP2024534420A/ja
Publication of JP2024534420A5 publication Critical patent/JP2024534420A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024516798A 2021-09-17 2022-09-15 環状スルホンアミドリボヌクレオチドレダクターゼ(rnr)阻害剤およびその使用 Pending JP2024534420A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163245718P 2021-09-17 2021-09-17
US63/245,718 2021-09-17
PCT/US2022/043660 WO2023043923A1 (en) 2021-09-17 2022-09-15 Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2024534420A true JP2024534420A (ja) 2024-09-20
JP2024534420A5 JP2024534420A5 (cg-RX-API-DMAC7.html) 2025-08-07

Family

ID=85603496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024516798A Pending JP2024534420A (ja) 2021-09-17 2022-09-15 環状スルホンアミドリボヌクレオチドレダクターゼ(rnr)阻害剤およびその使用

Country Status (11)

Country Link
US (1) US20250002486A1 (cg-RX-API-DMAC7.html)
EP (1) EP4401728A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024534420A (cg-RX-API-DMAC7.html)
KR (1) KR20240101555A (cg-RX-API-DMAC7.html)
CN (1) CN118434417A (cg-RX-API-DMAC7.html)
AU (1) AU2022345092A1 (cg-RX-API-DMAC7.html)
CA (1) CA3231660A1 (cg-RX-API-DMAC7.html)
IL (1) IL311458A (cg-RX-API-DMAC7.html)
MX (1) MX2024003258A (cg-RX-API-DMAC7.html)
TW (1) TW202328121A (cg-RX-API-DMAC7.html)
WO (1) WO2023043923A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023002453A2 (pt) 2020-08-12 2023-05-02 Boundless Bio Inc Composições de agente de via de estresse de replicação e métodos para tratar câncer
EP4587437A1 (en) * 2022-09-13 2025-07-23 Boundless Bio, Inc. Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof
EP4770642A2 (en) * 2023-09-01 2026-07-08 Boundless Bio, Inc. Ribonucleotide reductase (rnr) compositions and methods of use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002503657A (ja) * 1998-02-11 2002-02-05 デュポン ファーマシューティカルズ カンパニー メタロプロテイナーゼ阻害剤としての新規な環式スルホンアミド誘導体
WO2016189877A1 (en) * 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
WO2017209155A1 (ja) * 2016-05-31 2017-12-07 大鵬薬品工業株式会社 スルホンアミド化合物又はその塩
WO2019107386A1 (ja) * 2017-11-29 2019-06-06 大鵬薬品工業株式会社 抗腫瘍剤
WO2020241749A1 (ja) * 2019-05-29 2020-12-03 大鵬薬品工業株式会社 スルホンアミド化合物と免疫調節剤を用いるがん併用療法
JP2021504432A (ja) * 2017-11-29 2021-02-15 大鵬薬品工業株式会社 スルホンアミド化合物およびその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4301735A4 (en) * 2021-03-02 2025-05-21 Boundless Bio, Inc. Ribonucleotide reductase (rnr) inhibitors and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002503657A (ja) * 1998-02-11 2002-02-05 デュポン ファーマシューティカルズ カンパニー メタロプロテイナーゼ阻害剤としての新規な環式スルホンアミド誘導体
WO2016189877A1 (en) * 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
WO2017209155A1 (ja) * 2016-05-31 2017-12-07 大鵬薬品工業株式会社 スルホンアミド化合物又はその塩
WO2019107386A1 (ja) * 2017-11-29 2019-06-06 大鵬薬品工業株式会社 抗腫瘍剤
JP2021504432A (ja) * 2017-11-29 2021-02-15 大鵬薬品工業株式会社 スルホンアミド化合物およびその使用
WO2020241749A1 (ja) * 2019-05-29 2020-12-03 大鵬薬品工業株式会社 スルホンアミド化合物と免疫調節剤を用いるがん併用療法

Also Published As

Publication number Publication date
MX2024003258A (es) 2024-04-05
EP4401728A1 (en) 2024-07-24
IL311458A (en) 2024-05-01
US20250002486A1 (en) 2025-01-02
KR20240101555A (ko) 2024-07-02
WO2023043923A1 (en) 2023-03-23
CA3231660A1 (en) 2023-03-23
EP4401728A4 (en) 2025-08-06
TW202328121A (zh) 2023-07-16
CN118434417A (zh) 2024-08-02
AU2022345092A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
JP2025522294A (ja) ピリジンチェックポイントキナーゼ1(chk1)阻害剤及びその使用
JP2024520481A (ja) チェックポイントキナーゼ1(chk1)阻害剤およびその使用
WO2024118564A1 (en) Checkpoint kinase 1 (chk1) inhibitors and uses thereof
WO2023043923A1 (en) Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof
EA021126B1 (ru) Замещенные изохинолиноны и хинализолиноны
TW200906818A (en) Chemical compounds
JP7678929B2 (ja) ピリジノンmk2阻害剤及びその使用
EP3283077A2 (en) Bromodomain inhibitor
EP4626433A1 (en) Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof
WO2022187200A1 (en) Ribonucleotide reductase (rnr) inhibitors and uses thereof
JP2024534421A (ja) スルファミドリボヌクレオチドレダクターゼ(rnr)阻害剤およびその使用
JP2025531147A (ja) 環状スルホンアミドリボヌクレオチドレダクターゼ(rnr)阻害剤およびその使用
EA051928B1 (ru) Пиридиновые ингибиторы киназы 1 контрольной точки (chk1) и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250730

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260601